Company intelligence / Profile preview

AEGLE Partners

Woburn, Massachusetts, United States

Ownership: Private
Employees: ~6
Development stage: Other

Overview

AGLE-102 (MSC-EV therapy) is currently in a Phase 1/2 clinical trial for DEB and severe burns; preclinical data shows improved healing, reduced scarring, and minimized contraction.

Therapeutic areas: ImmunologyDermatology
Modalities: Extracellular Vesicles (EVs)ExosomesBiologic
Industry: Biotech

Partnerships

University of Miami (exclusive license on EV technology)United States Department of Defense CDMRP grant

Beyond the preview

Go deeper on AEGLE Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AEGLE Partners.

Explore the full profile